AzurRx (AZRX) Corporate Media Kit

28 2x2 Crossover study design enables rapid study execution 2.2 gram MS1819 safe and well tolerated 2.2 gram • MS1819 dose insufficient to achieve 80% CFA for all CF patients in study • Results consistent with CP study ~50% of patients Showed CFAs sufficient to reach non- inferiority with PERT Next Steps • Additional study to dose escalate to 4.4g/day • Use of enteric capsules to delay release of MS1819 in lower GI to preserve activity Conclusions from OPTION study to Support Phase 2b Clinical Trial Design